I.3 Ethionamide – drug-susceptible tuberculosis meningitis – EML and EMLc		
Draft recomm	endation	☐ X Recommended ☐ Not recommended Justification:
Does the proposed medicine address a relevant public health need?		☐ X Yes ☐ No ☐ Not applicable Comments:
efficacy/effect for the propos (this may be e application, ar	e evidence exist for the civeness of the medicine ed indication? vidence included in the end/or additional evidence ng the review process)	□ X Yes □ No □ Not applicable Comments:
safety/harms a proposed med (this may be e application, ar	e evidence exist for the associated with the licine? vidence included in the ad/or additional evidence ng the review process)	☐ X Yes ☐ No ☐ Not applicable Comments:
	adverse effects of at may require special	☐ Yes ☐ X No ☐ Not applicable Comments:
the safe, effect of the medicin (e.g. laborator	y diagnostic and/or sts, specialized training for	☐ Yes ☐ X No ☐ Not applicable Comments: For confirmed or suspected drug susceptible TBM TB DST widely available

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Are there any issues regarding cost, cost- effectiveness, affordability and/or access for the medicine in different settings?	☐ Yes ☐ X No ☐ Not applicable Comments:
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☐ Yes ☐ X No ☐ Not applicable Comments:
Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/who-guidelines)	□ X Yes □ No □ Not applicable Comments: